Otu, Akaninyene
Kosmidis, Chris
Mathioudakis, Alexander G.
Ibe, Chibuike
Denning, David W.
Article History
Received: 12 September 2022
Accepted: 15 November 2022
First Online: 20 January 2023
Declarations
:
: Denning and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company. He acts, or has recently acted, as a consultant to Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, Bright Angel Therapeutics, Cipla and Metis. He sits on the DSMB for a SARS CoV2 vaccine trial. In the last three years, he has been paid for talks on behalf of Dynamiker, Hikma, Gilead, Merck, Mylan and Pfizer. The other co-authors have no conflict of interest to declare.
: Not applicable.